Dyslipidemia

Drs Erin D. Michos, Matthew J. Budoff, Paul S. Jellinger, and Yehuda Handelsman, share their approach to incorporating guideline recommendations for the management of patients with ASCVD and hypercholesterolemia in clinical practice.

Dr Christie Ballantyne leads a discussion on how the management of patients with ASCVD and hypercholesterolemia has changed over the years.

Each weight-loss regimen had similar success in obesity management, regardless of patients reducing their calorie consumption through time-restricted eating or through calorie restriction alone.

Yehuda Handelsman, MD; Christie Ballantyne, MD; Paul S. Jellinger, MD, MACE; and Erin D. Michos, MD, MHS, comment on the impact of diabetes on chronic kidney disease and cardiovascular disease.

Matthew J. Budoff, MD; Christie Ballantyne, MD; and Paul S. Jellinger, MD, MACE, discuss the incidence and prevalence of atherosclerotic cardiovascular diseases (ASCVD) associated with hypercholesterolemia and risk factors for disease.

No evidence of lower Lp(a)-associated risks in hormone therapy users versus nonusers was observed.

Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.

Viet Le, PA-C, provides perspective on an ACC.22 study examining long-term risk of MACE based on alcohol consumption and whether or not the patient had a history of statin use.

An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.

A favorable lifestyle is associated with a lower risk of coronary artery disease in carriers and noncarriers of FH variants.

Results of the meta-analysis indicate the absolute risk reductions seen with statin therapy were notably lower than the relative risk reductions achieved with statin therapy.

An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.

A new study suggests use of apixaban was associated with a lower rate of rehospitalization for VTE compared with warfarin in patients with VTE requiring extended anticoagulation.

Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

A meta-analysis of data from more than 4 million patients suggests the prevalence of statin therapy may be overdiagnosed and provides insight into risk factors associated with increased risk of intolerance.

Findings from REDUCE-IT show icosapent ethyl was projected to be cost-effective compared with standard care in patients with high CV risk despite statin therapy.

A new study in JAMA Network Open provides an overview of the cost-effectiveness of icosapent ethyl at multiple prices in high-risk patients with hypertriglyceridemia despite statin therapy.

Data show atherosclerotic burden was heterogeneous across LDL-C levels and risk is shown to be consistently associated with plaque burden.

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.

No difference was observed between atrial shunt placement and sham in the endpoint of CVD death, non-fatal ischemic stroke at 12 months, and rate of total heart failure events at 24 months.

Analysis of real-world registry data presented at ISC 2022 provide insight into the risk of intracranial hemorrhage with tenecteplase versus alteplase in patients with acute ischemic stroke.

Data from an analysis of the ALSPAC cohort suggests arterial stiffness in adolescence could cause insulin resistance and dyslipidemia in young adulthood.